Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 1;48(7):303-305.
doi: 10.1097/ICL.0000000000000912. Epub 2022 Jun 3.

Recombinant Human Nerve Growth Factor for Pediatric Neurotrophic Keratopathy

Affiliations
Case Reports

Recombinant Human Nerve Growth Factor for Pediatric Neurotrophic Keratopathy

Duangratn Niruthisard et al. Eye Contact Lens. .

Abstract

A 4-year-old boy presented with right neurotrophic corneal ulcer, lagophthalmos, and facial palsy 8 months after neurosurgery for synchronous brain tumors. Initial treatment with topical antibiotics, topical corticosteroids, lubrication, and lateral tarsorrhaphy successfully treated the corneal epithelial defect; however, the cornea continued to demonstrate diffuse epitheliopathy and a dense stromal opacity and remained insensate on Cochet-Bonnet esthesiometry. After a course of topical cenegermin, central corneal sensation normalized, and the corneal epitheliopathy was markedly improved. Two years after the completion of cenegermin, corneal sensation was maintained; there were no recurrences of epithelial defects, and the stromal opacity had markedly improved. In vivo confocal microscopy (IVCM) demonstrated the presence of subbasal corneal innervation. This report highlights the safety and prolonged effects of cenegermin for the treatment of pediatric iatrogenic neurotrophic keratopathy, as evidenced by the clinical course and IVCM.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding or conflicts of interest to disclose.

Similar articles

Cited by

  • The use of rh-NGF in the management of neurotrophic keratopathy.
    Roszkowska AM, Spinella R, Calderone A, Sindoni M, Wowra BH, Kozak M, Sajak-Hydzik K, Aliò J. Roszkowska AM, et al. Front Ophthalmol (Lausanne). 2024 Jul 8;4:1408587. doi: 10.3389/fopht.2024.1408587. eCollection 2024. Front Ophthalmol (Lausanne). 2024. PMID: 39040985 Free PMC article. Review.

References

    1. Saad S, Abdelmassih Y, Saad R, et al. Neurotrophic keratitis: Frequency, etiologies, clinical management and outcomes. Ocul Surf 2020;18:231–236.
    1. Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 2018;125:1332–1343.
    1. Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: A multicenter randomized vehicle-controlled pivotal trial. Ophthalmology 2020;127:14–26.
    1. Pedrotti E, Bonetto J, Cozzini T, et al. Cenegermin in pediatric neurotrophic keratopathy. Cornea 2019;38:1450–1452.
    1. Fausto R, Ceccuzzi R, Micheletti E, et al. A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops. Medicine (Baltimore) 2020;99:e20816.

Publication types

LinkOut - more resources